Sanofi (NASDAQ: SNY) reported that its investigational drug efdoralprin alfa demonstrated superiority over standard-of-care therapy in treating alpha-1 antitrypsin deficiency ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA